Evidence map›Paper›PMID 42136912›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2026

Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.

R Gilmore, T Pham, R G Fernandes, S Lo, E K Wright, O Rosella, P De Cruz, B Andrew, A Vasudevan, K Gazelakis and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

R GilmoreDepartment of Gastroenterology Mater Hospital Brisbane Australia.ORCID https://orcid.org/0000-0002-6648-658X
T PhamDepartment of Gastroenterology Mater Hospital Brisbane Australia.
R G FernandesDepartment of Gastroenterology Mater Hospital Brisbane Australia.
S LoDepartment of Gastroenterology St. Vincent's Hospital Melbourne Australia.ORCID https://orcid.org/0000-0002-6129-5792
E K WrightDepartment of Gastroenterology St. Vincent's Hospital Melbourne Australia.ORCID https://orcid.org/0000-0003-3896-7826
O RosellaDepartment of Gastroenterology Austin Health Melbourne Australia.
P De CruzDepartment of Gastroenterology Austin Health Melbourne Australia.
B AndrewDepartment of Gastroenterology Eastern Health Melbourne Australia.
A VasudevanDepartment of Gastroenterology Eastern Health Melbourne Australia.
K GazelakisDepartment of Gastroenterology Monash Health Melbourne Melbourne Australia.
G T MooreDepartment of Gastroenterology Monash Health Melbourne Melbourne Australia.
L ThinDepartment of Gastroenterology Fiona Stanley Hospital Perth Australia.
K AuDepartment of Gastroenterology St Vincent's Hospital Sydney Australia.
S GhalyDepartment of Gastroenterology St Vincent's Hospital Sydney Australia.
C ChenDepartment of Gastroenterology Gold Coast University Hospital Gold Coast Australia.
W MohsenDepartment of Gastroenterology Gold Coast University Hospital Gold Coast Australia.
T GoodwinDepartment of Gastroenterology Alfred Health and Monash University Melbourne Australia.
M P SparrowDepartment of Gastroenterology Alfred Health and Monash University Melbourne Australia.ORCID https://orcid.org/0000-0003-2527-8044
M G WardDepartment of Gastroenterology Alfred Health and Monash University Melbourne Australia.
M ChewDepartment of Gastroenterology Northern Health Melbourne Australia.
M GargDepartment of Gastroenterology Northern Health Melbourne Australia.
E SheltonDepartment of Gastroenterology Yarra Gastroenterology Melbourne Australia.
I C LawranceFaculty of Health and Medical Sciences University of Western Australia Crawley Australia.
A ThoratPfizer Australia Sydney New South Wales Australia.
C da Fonseca PereiraPfizer Australia Sydney New South Wales Australia.
J BegunDepartment of Gastroenterology Mater Hospital Brisbane Australia.
Y K AnDepartment of Gastroenterology Mater Hospital Brisbane Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Tofacitinib, an oral Janus Kinase (JAK) inhibitor, has demonstrated efficacy for ulcerative colitis (UC) in clinical trials, but the optimal dosing regimen remains unclear. This study aims to assess the effectiveness and safety of tofacitinib for UC in a real-world Australian cohort focusing on outcomes of standard 8-week induction with 10 mg twice daily compared with extended 16-week induction. Methods: This multicenter study included patients with moderate-to-severe UC initiating tofacitinib between October 2020 and March 2021 across 13 Australian Inflammatory Bowel Disease centers. Clinical, biochemical, endoscopic, and adverse event (AE) outcomes were collected at baseline, week 8, week 16, and week 52, and stratified by duration of induction therapy. Results: A total of 124 patients (41% female; median age 41 [IQR 29-49] years) were identified, with 40% receiving standard induction and 60% receiving extended induction. Overall clinical response was achieved by 70% at week 8, 60% at week 16 and 68% at week 52. A significantly higher proportion of patients who received extended induction achieved clinical response by week 16 (69% vs. 45%, Conclusions: Tofacitinib was effective in an UC real-world Australian population and safety was consistent with its known profile. Clinical response at 16 and 52 weeks was significantly higher with extended induction dosing of tofacitinib.

Indexed as

extended inductionJanus Kinase inhibitortofacitinibulcerative colitis

Identifiers

PMID42136912
PMCPMC13167392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.